All In Biotech

Drug Trial Radar · NCT07284381

A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye Disease

A Multicenter, Double-masked, Randomized Study to Compare the Efficacy and Safety of the ABBV-444 Tear Formulation With REFRESH OPTIVE® Unit Dose in Patients With Dry Eye Disease

Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 261 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

261

Actual

Start

Dec 15, 2025

Primary completion

Aug 21, 2026

Study completion Aug 21, 2026

Sponsor

Lead sponsor
AbbVieAbbVie (ABBV)
Sponsor type
Industry
First posted
Dec 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Dry Eye Disease (DED) refers to a long-term condition that happens when there is not enough lubrication in your eyes. This can happen when your eye cannot make enough tears or if you make poor-quality tears. The purpose of this study is to compare the efficacy and safety of a new artificial tear formulation (ABBV-444) with Refresh Optive UD for 90 days in participants with Dry Eye Disease (DED. ABBV-444 is being developed for the treatment of Dry Eye Disease (DED). Participants will be placed into 1 of 2 treatment arms. Each group receives different treatment. Adult participants diagnosed with dry eye disease will be enrolled. Around 250 participants will be enrolled in the study at approximately 20 sites across the US In this study, participants first complete a 7-day run-in period using REFRESH PLUS® eye drops. Those eligible are then randomized to receive ABBV-444 eye drops or REFRESH OPTIVE® Unit Dose eye drops. Participants in both arms will receive treatment for a 90-day treatment period. There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend multiple required study visits during the study at the study site. The effect of the treatment will be checked by medical assessments and questionnaires.

Conditions

  • Dry Eye Disease

Interventions

  • ABBV-444Drug

    Topical eye drop

  • REFRESH OPTIVE UDDrug

    Topical eye drop

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from Baseline in Ocular Surface Disease Index (OSDI) ScoreTime frame: Baseline to Day 90
  2. Number of Participants with Adverse Events (AEs)Time frame: Baseline to Day 90

Locations

20 sites in 1 country. Site status is shown where the registry gives one.

  • Trinity Research Group /ID# 279914

    Dothan, Alabama

  • Arizona Eye Center - West Ray Road /ID# 267993

    Chandler, Arizona

  • Canyon City Eyecare /ID# 267948

    Azusa, California

  • Global Research Management /ID# 267980

    Glendale, California

  • Lakeside Vision Center /ID# 268544

    Irvine, California

  • Eye Research Foundation /ID# 267931

    Newport Beach, California

  • Lee Shettle Eye and Hearing /ID# 268118

    Largo, Florida

  • Clayton Eye Center /ID# 268097

    Morrow, Georgia

  • Coastal Research Associates - Roswell /ID# 279915

    Roswell, Georgia

  • Kannarr Eye Care /ID# 267979

    Pittsburg, Kansas

  • Butchertown Clinical Trials /ID# 267887

    Louisville, Kentucky

  • Moyes Eye Centers /ID# 267944

    Kansas City, Missouri

  • Northern New Jersey Eye Institute /ID# 267974

    South Orange, New Jersey

  • Rochester Ophthalmological Group - Rochester /ID# 268374

    Rochester, New York

  • Core Inc /ID# 267946

    Shelby, North Carolina

  • Scott and Christie and Associates /ID# 268119

    Cranberry Township, Pennsylvania

  • Southern College of Optometry /ID# 267971

    Memphis, Tennessee

  • Total Eye Care - Memphis /ID# 268327

    Memphis, Tennessee

  • Advancing Vision Research - Smyrna - Stonecrest Parkway /ID# 267939

    Smyrna, Tennessee

  • Piedmont Eye Center /ID# 267929

    Lynchburg, Virginia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.